These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 11980521)

  • 1. Timing of new black box warnings and withdrawals for prescription medications.
    Lasser KE; Allen PD; Woolhandler SJ; Himmelstein DU; Wolfe SM; Bor DH
    JAMA; 2002 May; 287(17):2215-20. PubMed ID: 11980521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
    Frank C; Himmelstein DU; Woolhandler S; Bor DH; Wolfe SM; Heymann O; Zallman L; Lasser KE
    Health Aff (Millwood); 2014 Aug; 33(8):1453-9. PubMed ID: 25092848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-review deadlines and safety problems.
    Carpenter D; Zucker EJ; Avorn J
    N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
    Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings.
    Cook DM; Gurugubelli RK; Bero LA
    Drug Saf; 2009; 32(11):1057-66. PubMed ID: 19810777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
    Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
    Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety-related regulatory actions for biologicals approved in the United States and the European Union.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Schellekens H; Leufkens HG; Egberts AC
    JAMA; 2008 Oct; 300(16):1887-96. PubMed ID: 18940975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.
    Ehrenpreis ED; Ciociola AA; Kulkarni PM;
    Am J Gastroenterol; 2012 Apr; 107(4):501-4. PubMed ID: 22475958
    [No Abstract]   [Full Text] [Related]  

  • 9. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
    Yeh JS; Sarpatwari A; Kesselheim AS
    Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugs.
    Ikeda J; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1393-1401. PubMed ID: 30094880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of newly approved drugs: implications for prescribing.
    Temple RJ; Himmel MH
    JAMA; 2002 May; 287(17):2273-5. PubMed ID: 11980528
    [No Abstract]   [Full Text] [Related]  

  • 12. New and incremental FDA black box warnings from 2008 to 2015.
    Solotke MT; Dhruva SS; Downing NS; Shah ND; Ross JS
    Expert Opin Drug Saf; 2018 Feb; 17(2):117-123. PubMed ID: 29215916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Social Media in Detecting Drug Safety-Related New Black Box Warnings, Labeling Changes, or Withdrawals: Scoping Review.
    Lee JY; Lee YS; Kim DH; Lee HS; Yang BR; Kim MG
    JMIR Public Health Surveill; 2021 Jun; 7(6):e30137. PubMed ID: 34185021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
    Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
    Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Black box warnings: what do they mean to pharmacists and patients.
    Martin CM; Borgelt L
    Consult Pharm; 2012 Jul; 27(7):482-92. PubMed ID: 22910129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
    Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
    Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between FDA black box warnings and Medicare formulary coverage changes.
    Dhruva SS; Karaca-Mandic P; Shah ND; Shaw DL; Ross JS
    Am J Manag Care; 2017 Sep; 23(9):e310-e315. PubMed ID: 29087169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies.
    Gafter-Gvili A; Tibau A; Raanani P; Shepshelovich D
    Acta Haematol; 2020; 143(1):73-77. PubMed ID: 31167178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
    Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.